Difference between revisions of "Denintuzumab mafodotin (SGN-CD19A)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Category:Intravenous chemotherapy" to "Category:Intravenous medications") |
||
| Line 7: | Line 7: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | [[Category:Intravenous | + | [[Category:Intravenous medications]] |
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
Revision as of 17:15, 25 July 2017
Mechanism of action
Antibody-drug conjugate
Preliminary studies
- Abstract: Andres Forero-Torres, Craig Moskowitz, Ranjana H. Advani, Bijal D. Shah, Ana Kostic, Tina M. Albertson, Larissa Sandalic, Baiteng Zhao, Michelle A. Fanale. Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). J Clin Oncol 32:5s, 2014 (suppl; abstr 8505) link to original abstract